Last reviewed · How we verify
NCT04595851
Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer Medications
NA trial testing Patient Reported Outcome Measure (PROM) in Chronic Myeloid Leukemia in 6 participants. Terminated before completion.
14 July 2022
Quick facts
| Lead sponsor | University of Michigan Rogel Cancer Center |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 6 |
| Start date | 26 March 2021 |
| Primary completion | 14 July 2022 |
| Estimated completion | 14 July 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Patient Reported Outcome Measure (PROM)
- Comprehensive Medication Review (CMR)
- Communications between oncology and primary care pharmacists
Conditions studied
- Chronic Myeloid Leukemia — all drugs for Chronic Myeloid Leukemia →
- Chronic Lymphocytic Leukemia — all drugs for Chronic Lymphocytic Leukemia →
- Multiple Chronic Conditions — all drugs for Multiple Chronic Conditions →
Sponsor
University of Michigan Rogel Cancer Center
Who can join
18 and older, any sex, with Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this study is to improve medication, symptom, and disease management of patients with hematological malignancies and multiple chronic conditions (2 or more conditions in addition to cancer) through care coordination between pharmacists working in oncology practices and those working in primary care practices (Pharmacists Coordinated care Oncology Model \[PCOM\]). This is a pilot study in which the investigators will examine the association between outcome measures, but the study design and sample size are insufficient to quantify the impact of OAA initiation or OAA adherence on adherence to chronic medications. This pilot study and data analyses are being done in preparation for a larger, controlled study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04595851
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Myeloid Leukemia
Currently open trials in the same condition.
- NCT06817720 — Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chroni · Phase 2 · recruiting
- NCT07238712 — Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies · Phase 2 · recruiting
- NCT06453902 — TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients · Phase 2 · recruiting
- NCT06390306 — The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP · recruiting
- NCT06355583 — Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial · Phase 2 · recruiting
Other University of Michigan Rogel Cancer Center trials
Trials by the same sponsor.
- NCT06914479 — Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and · Phase 1 · recruiting
- NCT07481344 — SunBeast: Evaluating UV Protective Behaviors and Education Interventions Among Ultrarunners · NA · not yet recruiting
- NCT07526545 — Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial · NA · not yet recruiting
- NCT07443943 — A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive · Phase 2 · recruiting
- NCT07365007 — A Virtually Delivered Diet Intervention (LASO-3) for the Improvement of Chemotherapy-Induced Peripheral Neuropathy in Ca · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04595851 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Michigan Rogel Cancer Center
- Last refreshed: 22 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04595851.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing